Product nameAnti-HMW Kininogen antibody
See all HMW Kininogen primary antibodies
DescriptionRabbit polyclonal to HMW Kininogen
Tested applicationsSuitable for: ICC/IF, WB, IP, ELISA, RIAmore details
Species reactivityReacts with: Human
HMW Kininogen purified from human plasma
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.01% Thimerosal (merthiolate)
Constituents: 50% Glycerol, PBS, pH 7.5
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab79653 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 5 µg/ml.|
|WB||Use a concentration of 20 µg/ml. Predicted molecular weight: 72 kDa.|
|IP||Use at an assay dependent dilution.|
|ELISA||Use a concentration of 3 - 8 µg/ml.|
|RIA||Use a concentration of 3 - 8 µg/ml.|
Function(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Tissue specificitySecreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
Involvement in diseaseDefects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
Sequence similaritiesContains 3 cystatin domains.
modificationsBradykinin is released from kininogen by plasma kallikrein.
Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
Phosphorylation sites are present in the extracelllular medium.
N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
- Alpha 2 thiol proteinase inhibitor antibody
- Alpha-2-thiol proteinase inhibitor antibody
- BDK antibody
ICC/IF image of ab79653 stained HeLa cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab79653, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Wang Q et al. The blood fluke Schistosoma mansoni cleaves the coagulation protein high molecular weight kininogen (HK) but does not generate the vasodilator bradykinin. Parasit Vectors 11:182 (2018). WB . Read more (PubMed: 29540224) »
- Hersrud SL et al. Plasma biomarkers for neuronal ceroid lipofuscinosis. FEBS J 283:459-71 (2016). Read more (PubMed: 26565144) »